Document is current
Any future updates will be listed below
-
Authors
Somerville, Emma N.
Krohn, Lynne
Senkevich, Konstantin
Yu, Eric
Ahmad, Jamil
Asayesh, Farnaz
Ruskey, Jennifer A.
Spiegelman, Dan
Fahn, Stanley
Waters, Cheryl
Sardi, S. Pablo
Alcalay, Roy N.
Gan-Or, Ziv
-
Funding
Funding for this research was provided by:
Michael J. Fox Foundation for Parkinson's Research (020700, 020700)
National Institutes of Health (K02NS080915, UL1 TR000040)
Consortium canadien en neurodégénérescence associée au vieillissement (049-14)
Canada First Research Excellence Fund (247908)
- License Information
-
More Information
Article History
Received: 15 May 2024
Accepted: 23 April 2025
First Online: 29 April 2025
Declarations
:
: All authors have read and consented to publish this manuscript.
: Z.G.O received consultancy fees from Lysosomal Therapeutics Inc. (LTI), Idorsia, Prevail Therapeutics, Ono Therapeutics, Denali, Handl Therapeutics, Neuron23, Bial Biotech, Bial, UCB, Capsida, Vanqua bio, Congruence Therapeutics, Takeda, Jazz Guidepoint, Lighthouse and Deerfield.
: Informed consent forms were signed by all participants prior to entering their respective studies, and the study protocol was approved by the institutional review boards.
